pfizer glp 1 drug The next breakthrough in weight-loss medicine may not be a stronger drug. It may simply be a people are more likely to keep taking. Pfizer's experimental obesity treatment, berobenatide, could reduce Pfizer pulls out of GLP-1

In this review, we highlight current clinical trials in neurological disorders and conclude by discussing therapeutic opportunities and challenges for sulforaphane

The findings underscore glutathione's protective function in brain health and indicate that stress-related pathways affecting antioxidant systems may represent new avenues for medication development in treating depression

Despite mounting evidence of this connection, Novo Nordisks current warning labels for Ozempic and Wegovy do not list NAION as a specific risk, mentioning only general vision changes among potential risks a disclosure many patients and legal experts argue falls far short of adequate warning about permanent blindness

The gap between biohacker enthusiasm and clinical evidence remains vast, but specific compounds merit continued attention for prevention-focused research

J Clin Invest 128:33413355 Robberecht W, Philips T (2013) The changing scene of amyotrophic lateral sclerosis